8-K: Cardinal Health Reports Strong FY26 Results, Exceeds Guidance

Cardinal Health announced a 6% revenue increase to $63.7 billion for Q4 FY26 and provided FY27 non-GAAP EPS guidance projecting 13-15% growth.

Summary

• Cardinal Health reported a 6% increase in fourth-quarter fiscal year 2026 revenue, reaching $63.7 billion, and a 70% increase in GAAP diluted EPS to $1.70.
• Excluding a one-time tariff refund, non-GAAP diluted EPS rose 25% to $2.60 in Q4 FY26.
• For the full fiscal year 2026, revenue grew 14% to $254.2 billion, with non-GAAP diluted EPS increasing 37% to $11.26 (or 33% excluding the tariff refund).
• Operating cash flow for FY26 was $5.2 billion, and adjusted free cash flow was $5.0 billion.
• The company completed an additional $350 million share repurchase and received board approval for a $5.0 billion increase to its repurchase program.
• Fiscal year 2027 non-GAAP EPS guidance is projected at 13% to 15% growth, translating to $12.40 to $12.60 per share, exceeding the company's long-term guidance.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant year-over-year growth in revenue and earnings, robust cash flow, and optimistic future guidance that exceeds long-term targets.

Positives

• Fourth-quarter revenue increased by 6% to $63.7 billion.
• Fourth-quarter GAAP diluted EPS saw a significant increase of 70% to $1.70.
• Fourth-quarter non-GAAP diluted EPS, excluding a one-time tariff refund, increased by 25% to $2.60.
• Full fiscal year 2026 revenue grew by 14% to $254.2 billion.
• Full fiscal year 2026 non-GAAP diluted EPS increased by 37% to $11.26 (33% excluding tariff refund).
• Operating cash flow for FY26 was a strong $5.2 billion.
• Adjusted free cash flow for FY26 was $5.0 billion.
• Board approved a $5.0 billion increase to the share repurchase program, bringing the total authorization to $6.4 billion.
• Fiscal year 2027 non-GAAP EPS guidance of 13% to 15% growth ($12.40 to $12.60) exceeds the company's long-term guidance.

Negatives

• Fourth-quarter revenue for the Global Medical Products and Distribution segment decreased by 2% to $3.1 billion, primarily due to lower distribution volumes and the recognition of the IEEPA tariff refund repayment to customers.
• The company recognized a pre-tax goodwill impairment charge of $184 million related to the Navista & ION reporting unit within the Pharma segment in fiscal year 2026.

Risks

• Risks associated with tariffs, including the potential inability to offset increased costs.
• Competitive pressures in various lines of business, potentially leading to reduced customer purchases or contract terminations/non-renewals.
• Litigation matters, including Department of Justice investigations focused on potential violations of the Anti-Kickback Statute and False Claims Act.
• Events outside of control, such as weather or geopolitical events, impacting product costs, supply delays, or manufacturing delays.
• The performance of the generics program, including the rate of generic deflation and the ability to offset it.
• Uncertainties associated with the pricing of branded pharmaceuticals, including those arising from proposed or final regulatory changes.
• Risks related to the integration and operation of recently acquired entities and the execution of the GMPD Improvement Plan initiatives.

Future Outlook

For fiscal year 2027, Cardinal Health projects non-GAAP diluted EPS to grow between 13% and 15%, reaching $12.40 to $12.60 per share, which is above the company's long-term EPS guidance. This outlook incorporates the estimated impact of recent and announced tuck-in acquisitions.

Management Comments

• "Fiscal 2026 was a standout year for Cardinal Health and I am pleased with our strong fourth quarter results," said Jason Hollar, CEO of Cardinal Health.
• "The broad-based operational strength for the year, with all five of our operating segments growing profit double-digits, even before recognition of IEEPA tariff recoveries in GMPD, reflects the disciplined execution of our strategy and our investments for growth."
• "We enter Fiscal 2027 with momentum and confidence in our ability to deliver continued shareholder value creation."

Industry Context

StockSavvy.ai notes that Cardinal Health's performance aligns with a trend of increased demand for healthcare distribution and services, driven by an aging population and ongoing healthcare system complexities. The company's strategic acquisitions and focus on operational efficiency are key differentiators in a competitive market.

Comparison to Industry Standards

• While specific comparable company data is not provided in the filing, Cardinal Health's reported 14% revenue growth and 33-37% non-GAAP EPS growth for FY26 generally outperform many peers in the broader healthcare distribution sector, which often experiences more moderate single-digit growth rates.
• The company's strong operating cash flow of $5.2 billion and adjusted free cash flow of $5.0 billion indicate robust financial health, likely placing it favorably against industry benchmarks for cash generation relative to revenue.
• The projected 13-15% non-GAAP EPS growth for FY27 is notably strong and suggests Cardinal Health is outperforming industry expectations for future earnings growth in the healthcare services and distribution space.

Legal Proceedings

• Department of Justice investigations focused on potential violations of the Anti-Kickback Statute and False Claims Act.

Stakeholder Impact

• Shareholders: Benefit from increased share repurchase authorization ($5.0 billion incremental) and a regular quarterly dividend of $0.5158 per share.
• Employees: Potential positive impact from company growth and strategic execution, though specific details are not provided.
• Customers: Benefit from improved operational efficiency and potential for continued service levels, though some segments saw revenue declines.
• Suppliers: Continued business relationship with a growing company, though specific impacts are not detailed.
• Creditors: Strengthened financial position with robust cash flow and increased share repurchases may indicate reduced debt servicing pressure.

Next Steps

• Continue execution of strategy and investments for growth.
• Deliver continued shareholder value creation in Fiscal Year 2027.
• Integrate recently completed tuck-in acquisition of Strive Medical.
• Integrate announced tuck-in acquisition of the Diabetes Health business of AdaptHealth.
• Open new distribution center in Indianapolis in 2027.
• Continue regular quarterly dividend payments.

Key Dates

Recommendation

The company delivered strong results and provided optimistic guidance, exceeding expectations. However, the presence of ongoing litigation risks (DOJ investigations) and the inherent cyclicality and competitive pressures within the healthcare distribution sector warrant a cautious approach. While the financial performance is positive, the existing risks suggest a 'hold' rather than an immediate 'buy' recommendation until these legal uncertainties are resolved.

Keywords

Cardinal Health, Healthcare Distribution, Pharmaceuticals, Medical Products, Specialty Solutions, Earnings Report, Fiscal Year 2026, Fiscal Year 2027 Guidance